Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Des D. Cashell"'
Autor:
David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth
Supplementary Figure 1. Participant Flow Diagram
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a4f3ddb7682626f66115790cb0108aba
https://doi.org/10.1158/1078-0432.22476300.v1
https://doi.org/10.1158/1078-0432.22476300.v1
Autor:
David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth
Purpose:The activating mutation AKT1E17K occurs in approximately 7% of estrogen receptor–positive (ER+) metastatic breast cancer (MBC). We report, from a multipart, first-in-human, phase I study (NCT01226316), tolerability and activity of capivaser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28c1b1cc28095071714876d36a725e47
https://doi.org/10.1158/1078-0432.c.6529365.v1
https://doi.org/10.1158/1078-0432.c.6529365.v1
Autor:
David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth
Supplementary Figure 3. AKT1E17K Allele Frequency (AF) Distribution and Median AF for patients with available ctDNA NGS data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3cc68c5e9ff3cae038afb89d5bd3f604
https://doi.org/10.1158/1078-0432.22476294
https://doi.org/10.1158/1078-0432.22476294
Autor:
David M. Hyman, José Baselga, Sarat Chandarlapaty, Barry S. Taylor, Maurizio Scaltriti, Udai Banerji, Gaia Schiavon, Vicky Rowlands, Martin Pass, Michele Moschetta, Robert McEwen, Rhiannon Maudsley, Justin P.O. Lindemann, Joana Hauser, Andrew Foxley, Elza C. de Bruin, Claire Corcoran, Des D. Cashell, Alan Barnicle, Jack Ashton, Helen J. Ambrose, Laura Biganzoli, Marie-Paule Sablin, Ingrid A. Mayer, Eva M. Ciruelos, Mafalda Oliveira, Kenji Tamura, Lillian M. Smyth
Supplementary tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55a0265a5795450271c65b9e3919ea10
https://doi.org/10.1158/1078-0432.22476291.v1
https://doi.org/10.1158/1078-0432.22476291.v1
Autor:
Ingrid A. Mayer, Sarat Chandarlapaty, Gaia Schiavon, Vicky Rowlands, Martin Pass, Elza C. de Bruin, Helen Ambrose, Claire Corcoran, Andrew Foxley, Kenji Tamura, David M. Hyman, Maurizio Scaltriti, Eva Ciruelos, Jack Ashton, José Baselga, Lillian M. Smyth, Joana Hauser, Justin P.O. Lindemann, Des D. Cashell, Michele Moschetta, Robert McEwen, Mafalda Oliveira, Barry S. Taylor, Udai Banerji, Rhiannon Maudsley, Alan Barnicle, Laura Biganzoli, Marie-Paule Sablin
Publikováno v:
Clinical Cancer Research. 26:3947-3957
Purpose:The activating mutation AKT1E17K occurs in approximately 7% of estrogen receptor–positive (ER+) metastatic breast cancer (MBC). We report, from a multipart, first-in-human, phase I study (NCT01226316), tolerability and activity of capivaser
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6b1f335fee045aa56d162db1a23a880b
https://doi.org/10.1158/1078-0432.ccr-19-3953
https://doi.org/10.1158/1078-0432.ccr-19-3953
Autor:
Lillian M, Smyth, Kenji, Tamura, Mafalda, Oliveira, Eva M, Ciruelos, Ingrid A, Mayer, Marie-Paule, Sablin, Laura, Biganzoli, Helen J, Ambrose, Jack, Ashton, Alan, Barnicle, Des D, Cashell, Claire, Corcoran, Elza C, de Bruin, Andrew, Foxley, Joana, Hauser, Justin P O, Lindemann, Rhiannon, Maudsley, Robert, McEwen, Michele, Moschetta, Martin, Pass, Vicky, Rowlands, Gaia, Schiavon, Udai, Banerji, Maurizio, Scaltriti, Barry S, Taylor, Sarat, Chandarlapaty, José, Baselga, David M, Hyman
Publikováno v:
Clin Cancer Res
PURPOSE: The activating mutation AKT1(E17K) occurs in ~7% of ER+ metastatic breast cancer (MBC). We report, from a multipart, first-in-human, Phase I study (NCT01226316), tolerability and activity of capivasertib, an oral AKT inhibitor, as monotherap
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2f90b1de568f19fbb00f4b3c50ea4472
https://pubmed.ncbi.nlm.nih.gov/32312891
https://pubmed.ncbi.nlm.nih.gov/32312891